1. Scrip
  2. >>Business
  3. >>Stock Watch

Stock Watch: Spanners In The Works For Q4 Results

Missed Estimates And Accounting Regulations Could Foul The Pitch

 
• By Andy Smith

While the implications of the US Inflation Reduction Act are the focus of the sector’s concern this year, another regulatory development will impact earnings sooner.

Stock Watch Image, Andy Smith
ANDY SMITH OFFERS A LIFE SCIENCE INVESTOR'S PERSPECTIVE ON BIOPHARMA BUSINESS

The fourth-quarter and full-year 2022 earnings season for life science companies is just around the corner. This quarter in particular is usually something to look forward to because sales are typically better in the final quarter of the year. Companies might also incorporate the boost in revenues from early January’s list price increases into their full-year financial guidance as they report fourth-quarter sales that benefited from drug wholesalers and big pharmacy groups over-ordering in the fourth quarter in anticipation of those price hikes – just as they did at the start of the pandemic when supply chain disruption was anticipated.

That was in the days when list prices meant more than just determining the out-of-pocket cost for those privately and...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Stock Watch

Stock Watch: Pharma Financial Forecasts Cannot Withstand Headwinds Forever

 
• By Andy Smith

Pharma company financial guidance emerged largely unscathed from a first quarter punctured by a weakening US dollar and threats of import tariffs on drugs. With other pressures either already evident or on the horizon, guidance revisions may be unavoidable.

Stock Watch: US CAR-T And Vaccine Actions: Net Negative For Access

 
• By Andy Smith

Relaxing CAR-T restrictions may not be an access panacea because of patient fragility and lack of payer incentive. Conversely, the ACIP’s recent recommendation on Thiomersal-containing flu vaccines is probably the thin edge of a more restrictive wedge.

Stock Watch: Syncona’s Wild Ride Exposes Suspect Strategies

 
• By Andy Smith

A track record of positive portfolio performance is described as an investment management skill. Taking difficult divestment decisions early, in challenging markets and outperforming benchmarks, are hallmarks of this skill. Syncona and Woodford Patient Capital offer useful case studies.

Stock Watch: When The Biotech Bandwagon Music Stops

 
• By Andy Smith

The number of viable biotech companies exploiting a particular technology should be limited by intellectual property but the number of biotech IPOs exploiting that same technology always seems greater than those with freedom to operate.

More from Business

IPO Update: With Just Two Small Offerings In Q2, What’s Next?

 
• By Mandy Jackson

With low valuations for biopharma companies that recently went public and little hope of a near-term turnaround as uncertainty lingers, IPO numbers may stay low for the rest of 2025.

Actuate Is Looking For A Buyer To Advance Pancreatic Cancer Candidate

 
• By Jessica Merrill

After presenting encouraging Phase II data on the GSK-3 inhibitor elraglusib at ASCO, Actuate Therapeutics is hoping to hold a pre-NDA meeting with the US FDA.

Novartis Upbeat Even With Entresto Expiry Looming

 
• By Kevin Grogan

Swiss major confident that new oncology drugs will fill revenue gap.